Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia.
Dengue viruses (DEN), causative agents of dengue fever (DF) and more severe dengue hemorrhagic fever (DHF)/dengue shock syndrome, infect over 100 million people every year. Among those infected, up to one-half million people develop DHF, which requires an extensive hospital stay. Recent reports indicate that there is a significant correlation between virus titer in the bloodstream of infected individuals and the severity of the disease, especially the development of DHF. This suggests that if there is a procedure to reduce viremia in infected subjects, then the severity of the disease may be controlled during the critical early stages of the disease before it progresses to DHF. We have generated bispecific mAb complexes (heteropolymer(s), HP), which contain a mAb specific for the DEN envelope glycoprotein cross-linked with a second mAb specific for the primate E complement receptor 1. These HP facilitate rapid binding of DEN to human and monkey E in vitro, with approximately 90% bound within 5 min. Furthermore, in a passive viremia monkey model established by continuous steady state infusion of DEN, injection of HP during the steady state promoted rapid binding of DEN to the E, followed by subsequent clearance from the vascular system. Moreover, HP previously infused into the circulation is capable of efficiently capturing a subsequent challenge dose of DEN and binding it to E. These data suggest that HP potentially can be useful for alleviating DEN infection-associated symptoms by reducing titers of free virus in the vascular system.
Hahn
C S
CS
Beirne B. Carter Center for Immunology Research, Department of Microbiology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA. Csh2S@virginia.edu
French
O G
OG
Foley
P
P
Martin
E N
EN
Taylor
R P
RP
D000818:Animals; D018033:Antibodies, Bispecific / Q000008:administration & dosage* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000378:metabolism; D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000378:metabolism; D001666:Binding Sites, Antibody; D001667:Binding, Competitive / Q000276:immunology; D002460:Cell Line; D006224:Cricetinae; D003715:Dengue / Q000276:immunology / Q000628:therapy; D003716:Dengue Virus / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D006825:Hybridomas; D007116:Immunization, Passive; D007262:Infusions, Intravenous; D008252:Macaca fascicularis; D012367:RNA, Viral / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013462:Sulfur Radioisotopes / Q000378:metabolism; D019562:Viral Load; D014766:Viremia / Q000276:immunology* / Q000628:therapy*
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D012367:RNA, Viral; D013462:Sulfur Radioisotopes